{"id": "article-30379_0", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Continuing Education Activity", "content": "Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed antidepressants. Other clinical indications for SSRI use include anxiety disorders, obsessive-compulsive disorder, panic disorders, and eating disorders. Compared to their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are associated with fewer toxic effects. This activity describes the uses, mode of action and adverse effects of SSRIs and highlights the role of the interprofessional team in the management of these patients.", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Continuing Education Activity. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed antidepressants. Other clinical indications for SSRI use include anxiety disorders, obsessive-compulsive disorder, panic disorders, and eating disorders. Compared to their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are associated with fewer toxic effects. This activity describes the uses, mode of action and adverse effects of SSRIs and highlights the role of the interprofessional team in the management of these patients."}
{"id": "article-30379_1", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Continuing Education Activity", "content": "Objectives: Identify the mode of action of the SSRIs. Review the toxic effects of SSRIs. Summarize the treatment options of SSRI toxicity. Outline interprofessional team strategies for improving care coordination and outcomes in patients with SSRI toxicity. Access free multiple choice questions on this topic.", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Continuing Education Activity. Objectives: Identify the mode of action of the SSRIs. Review the toxic effects of SSRIs. Summarize the treatment options of SSRI toxicity. Outline interprofessional team strategies for improving care coordination and outcomes in patients with SSRI toxicity. Access free multiple choice questions on this topic."}
{"id": "article-30379_2", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Introduction", "content": "Selective\u00a0serotonin\u00a0reuptake\u00a0inhibitors (SSRIs) are commonly prescribed antidepressants. Other clinical indications for SSRI use\u00a0include anxiety disorders, obsessive-compulsive disorder, panic disorders, and eating disorders. Compared to their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are associated with fewer toxic effects. [1]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Introduction. Selective\u00a0serotonin\u00a0reuptake\u00a0inhibitors (SSRIs) are commonly prescribed antidepressants. Other clinical indications for SSRI use\u00a0include anxiety disorders, obsessive-compulsive disorder, panic disorders, and eating disorders. Compared to their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are associated with fewer toxic effects. [1]"}
{"id": "article-30379_3", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Introduction", "content": "Individual SSRIs differ from each other regarding structure and pharmacokinetics but, as a group, they act by potentiating the action of serotonin. SSRIs are less cardiotoxic than many first-generation antidepressants, but there is still evidence that\u00a0they\u00a0inhibit sodium, calcium, and potassium ion channels at concentrations near\u00a0therapeutic levels. [2] Citalopram and escitalopram are known to\u00a0cause QTc prolongation. [3] [4] There also have been reports of atrial fibrillation and bradycardia related to fluoxetine use. [5]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Introduction. Individual SSRIs differ from each other regarding structure and pharmacokinetics but, as a group, they act by potentiating the action of serotonin. SSRIs are less cardiotoxic than many first-generation antidepressants, but there is still evidence that\u00a0they\u00a0inhibit sodium, calcium, and potassium ion channels at concentrations near\u00a0therapeutic levels. [2] Citalopram and escitalopram are known to\u00a0cause QTc prolongation. [3] [4] There also have been reports of atrial fibrillation and bradycardia related to fluoxetine use. [5]"}
{"id": "article-30379_4", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Introduction", "content": "Adverse effects of SSRIs are vague and nonspecific but include hyponatremia, anorgasmia, sedation, stimulation, and gastric irritation. [6] [7] Seizures are uncommon but have been reported; Isbister et al. [8] reported a seizure incidence of 1.9%. They may also inhibit platelet secretion, aggregation, and plug formation. [9]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Introduction. Adverse effects of SSRIs are vague and nonspecific but include hyponatremia, anorgasmia, sedation, stimulation, and gastric irritation. [6] [7] Seizures are uncommon but have been reported; Isbister et al. [8] reported a seizure incidence of 1.9%. They may also inhibit platelet secretion, aggregation, and plug formation. [9]"}
{"id": "article-30379_5", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Introduction", "content": "Patients with adverse effects from SSRIs will present with a range of symptoms, and some researchers have advocated for the term \u201cserotonin toxicity\u201d rather than \u201cserotonin syndrome\u201d to highlight that this condition is a spectrum of symptoms rather than a single clinical entity. [10] [11] In patients with mild symptoms, the benefit they receive from the prescribed SSRI may outweigh the negative side effects.", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Introduction. Patients with adverse effects from SSRIs will present with a range of symptoms, and some researchers have advocated for the term \u201cserotonin toxicity\u201d rather than \u201cserotonin syndrome\u201d to highlight that this condition is a spectrum of symptoms rather than a single clinical entity. [10] [11] In patients with mild symptoms, the benefit they receive from the prescribed SSRI may outweigh the negative side effects."}
{"id": "article-30379_6", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Etiology", "content": "Serotonin toxicity is the most serious drug reaction from inadvertent or intentional SSRI overdose and can\u00a0be iatrogenic, caused\u00a0by the introduction of a serotonergic agent, increased dosing of an established serotonergic agent or after coadministration with another agent that increases serotonin activity. [12] The most severe cases\u00a0are caused\u00a0by combinations of drugs that enhance serotonin levels by acting through separate mechanisms, for example, a monoamine oxidase inhibitor and a serotonin reuptake inhibitor. [13]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Etiology. Serotonin toxicity is the most serious drug reaction from inadvertent or intentional SSRI overdose and can\u00a0be iatrogenic, caused\u00a0by the introduction of a serotonergic agent, increased dosing of an established serotonergic agent or after coadministration with another agent that increases serotonin activity. [12] The most severe cases\u00a0are caused\u00a0by combinations of drugs that enhance serotonin levels by acting through separate mechanisms, for example, a monoamine oxidase inhibitor and a serotonin reuptake inhibitor. [13]"}
{"id": "article-30379_7", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Etiology", "content": "Many medications affect serotonin levels by different overlapping mechanisms.\u00a0In addition to\u00a0SSRIs, ondansetron, methadone,\u00a0clomipramine, amitriptyline, dextromethorphan, fentanyl, meperidine, tramadol, trazodone, venlafaxine, and pentazocine increase serotonin levels by blocking reuptake. Medications that can increase serotonin levels by inhibiting serotonin metabolism include\u00a0linezolid, methylene blue, St. John's wort, or\u00a0monoamine oxidase inhibitors like\u00a0phenelzine, selegiline, and isocarboxazid. Methylenedioxymethamphetamine (MDMA) and mirtazapine enhance serotonin release. Tryptophan\u00a0is a serotonin precursor. Cocaine increases serotonin synthesis.\u00a0Buspirone, fentanyl, dihydroergotamine, lithium, lysergic acid diethylamide (LSD), metoclopramide and\u00a0triptans\u00a0stimulate serotonin receptors. [12] [14] [15] [16] Research is still ongoing\u00a0on the subject of opioid\u00a0safety with concomitant SSRI. [17] [18] [19] Studies have shown that synthetic opioids can inhibit SERT (serotonin transporter) but fentanyl and oxycodone, which have not shown inhibitory effects on SERT, have\u00a0been reported\u00a0anecdotally in\u00a0cases of serotonin toxicity. [20] [21]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Etiology. Many medications affect serotonin levels by different overlapping mechanisms.\u00a0In addition to\u00a0SSRIs, ondansetron, methadone,\u00a0clomipramine, amitriptyline, dextromethorphan, fentanyl, meperidine, tramadol, trazodone, venlafaxine, and pentazocine increase serotonin levels by blocking reuptake. Medications that can increase serotonin levels by inhibiting serotonin metabolism include\u00a0linezolid, methylene blue, St. John's wort, or\u00a0monoamine oxidase inhibitors like\u00a0phenelzine, selegiline, and isocarboxazid. Methylenedioxymethamphetamine (MDMA) and mirtazapine enhance serotonin release. Tryptophan\u00a0is a serotonin precursor. Cocaine increases serotonin synthesis.\u00a0Buspirone, fentanyl, dihydroergotamine, lithium, lysergic acid diethylamide (LSD), metoclopramide and\u00a0triptans\u00a0stimulate serotonin receptors. [12] [14] [15] [16] Research is still ongoing\u00a0on the subject of opioid\u00a0safety with concomitant SSRI. [17] [18] [19] Studies have shown that synthetic opioids can inhibit SERT (serotonin transporter) but fentanyl and oxycodone, which have not shown inhibitory effects on SERT, have\u00a0been reported\u00a0anecdotally in\u00a0cases of serotonin toxicity. [20] [21]"}
{"id": "article-30379_8", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Epidemiology", "content": "The American Association of Poison Control Centers reported over 50,000\u00a0overdose cases\u00a0in 2016 where SSRIs\u00a0were mentioned; of these reported cases, 102 were fatal, but in all but one of these fatalities\u00a0co-ingestants\u00a0were involved. [22] Sertraline and fluoxetine were the SSRIs most commonly taken in excess. [22] One study analyzing 469 SSRI overdoses reported serotonin toxicity in 14% of cases. [8]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Epidemiology. The American Association of Poison Control Centers reported over 50,000\u00a0overdose cases\u00a0in 2016 where SSRIs\u00a0were mentioned; of these reported cases, 102 were fatal, but in all but one of these fatalities\u00a0co-ingestants\u00a0were involved. [22] Sertraline and fluoxetine were the SSRIs most commonly taken in excess. [22] One study analyzing 469 SSRI overdoses reported serotonin toxicity in 14% of cases. [8]"}
{"id": "article-30379_9", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- History and Physical", "content": "Serotonin toxicity is a clinical diagnosis initially defined by the Sternbach criteria. Generally, these symptoms include neuromuscular excitation, autonomic stimulation and altered level of consciousness. The presence of generalized clonus\u00a0indicates\u00a0serotonin toxicity. [13] Neuromuscular symptoms are usually more prominent in the lower extremities. [15]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- History and Physical. Serotonin toxicity is a clinical diagnosis initially defined by the Sternbach criteria. Generally, these symptoms include neuromuscular excitation, autonomic stimulation and altered level of consciousness. The presence of generalized clonus\u00a0indicates\u00a0serotonin toxicity. [13] Neuromuscular symptoms are usually more prominent in the lower extremities. [15]"}
{"id": "article-30379_10", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- History and Physical", "content": "Due to the nonspecific nature of the Sternbach criteria,\u00a0the Hunt serotonin toxicity criteria were developed. The Hunt serotonin toxicity criteria decision rule describes 5 constellations of symptoms that define\u00a0serotonin toxicity [10] : Spontaneous clonus Inducible clonus and agitation or diaphoresis Ocular clonus with agitation or diaphoresis Tremor and hyperreflexia Ocular clonus, hypertonicity, and temperature greater than 38 C Besides signs and symptoms, a history suggestive of serotonin exposure or overdose\u00a0is required\u00a0to diagnose serotonin toxicity.", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- History and Physical. Due to the nonspecific nature of the Sternbach criteria,\u00a0the Hunt serotonin toxicity criteria were developed. The Hunt serotonin toxicity criteria decision rule describes 5 constellations of symptoms that define\u00a0serotonin toxicity [10] : Spontaneous clonus Inducible clonus and agitation or diaphoresis Ocular clonus with agitation or diaphoresis Tremor and hyperreflexia Ocular clonus, hypertonicity, and temperature greater than 38 C Besides signs and symptoms, a history suggestive of serotonin exposure or overdose\u00a0is required\u00a0to diagnose serotonin toxicity."}
{"id": "article-30379_11", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- History and Physical", "content": "Minor symptoms of serotonin toxicity include\u00a0vomiting, somnolence, mydriasis, or diaphoresis.\u00a0Someone can see severe symptoms (decreased level of consciousness, ECG changes, and seizures\u00a0with overdoses greater than 75 times the recommended daily dose. [23] The concentration of the different serotonin receptors is highest in the neuromuscular, autonomic nervous, and gastrointestinal (GI) systems, accounting for the variety of common adverse effects of serotonin excess. [14]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- History and Physical. Minor symptoms of serotonin toxicity include\u00a0vomiting, somnolence, mydriasis, or diaphoresis.\u00a0Someone can see severe symptoms (decreased level of consciousness, ECG changes, and seizures\u00a0with overdoses greater than 75 times the recommended daily dose. [23] The concentration of the different serotonin receptors is highest in the neuromuscular, autonomic nervous, and gastrointestinal (GI) systems, accounting for the variety of common adverse effects of serotonin excess. [14]"}
{"id": "article-30379_12", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Evaluation", "content": "Initial evaluation and treatment of a patient with serotonin toxicity are\u00a0similar to\u00a0any overdose, altered mental status, or poisoning patient with the establishment of intravenous access, initiation of cardiac monitoring, stabilization of vital signs, and fluid resuscitation. Diagnosis of serotonin toxicity is not only clinical but also a diagnosis of exclusion, therefore, even though diagnosis does not rely on any specific laboratory value, thorough testing to rule out other causes of altered mental status is essential. [12]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Evaluation. Initial evaluation and treatment of a patient with serotonin toxicity are\u00a0similar to\u00a0any overdose, altered mental status, or poisoning patient with the establishment of intravenous access, initiation of cardiac monitoring, stabilization of vital signs, and fluid resuscitation. Diagnosis of serotonin toxicity is not only clinical but also a diagnosis of exclusion, therefore, even though diagnosis does not rely on any specific laboratory value, thorough testing to rule out other causes of altered mental status is essential. [12]"}
{"id": "article-30379_13", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Treatment / Management", "content": "Nelson\u00a0et al. [24] established guidelines for out-of-hospital management of isolated SSRI overdose and recommended at-home observation of patients who were experiencing minor symptoms and had ingested less than 5 times their own prescribed dose or less than 5 times the initial adult dose in an SSRI-naive patient.\u00a0This should only be done\u00a0in close conjunction with a regional poison control center.", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Treatment / Management. Nelson\u00a0et al. [24] established guidelines for out-of-hospital management of isolated SSRI overdose and recommended at-home observation of patients who were experiencing minor symptoms and had ingested less than 5 times their own prescribed dose or less than 5 times the initial adult dose in an SSRI-naive patient.\u00a0This should only be done\u00a0in close conjunction with a regional poison control center."}
{"id": "article-30379_14", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Treatment / Management", "content": "Treatment is\u00a0largely\u00a0supportive and involves discontinuation of all serotonergic therapies, control of agitation with benzodiazepines and defervescence. [25] [12] Droperidol\u00a0and haloperidol should not be used to control agitation as these medications can worsen hyperthermia by inhibiting sweating through their anticholinergic properties. [26] In severe cases of serotonin toxicity where patients required endotracheal intubation and ventilatory support, hypertonicity, rigidity, and high-grade fever were evident. [12]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Treatment / Management. Treatment is\u00a0largely\u00a0supportive and involves discontinuation of all serotonergic therapies, control of agitation with benzodiazepines and defervescence. [25] [12] Droperidol\u00a0and haloperidol should not be used to control agitation as these medications can worsen hyperthermia by inhibiting sweating through their anticholinergic properties. [26] In severe cases of serotonin toxicity where patients required endotracheal intubation and ventilatory support, hypertonicity, rigidity, and high-grade fever were evident. [12]"}
{"id": "article-30379_15", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Treatment / Management", "content": "Muscular rigidity\u00a0is thought\u00a0to be the primary cause of hyperthermia and death so patients with severe symptoms should\u00a0be rapidly cooled. If benzodiazepines do not sufficiently control muscle spasm or temperature is greater than 41.1 C,\u00a0intubation with neuromuscular blockade and paralysis can\u00a0be considered. [12] In cases\u00a0refractory to supportive care,\u00a0cyproheptadine or chlorpromazine, which have anti-serotonergic properties, can be administered; although, it is unclear if\u00a0these medications\u00a0alter patient outcome. [27] [28] Cyproheptadine does not have an IV formulation and must, therefore,\u00a0be administered\u00a0via a nasogastric or orogastric tube. [29] There is no role for acetaminophen, NSAIDs, or aspirin in control of hyperthermia as\u00a0the increased temperature\u00a0is not caused\u00a0by a change in the hypothalamic temperature set point. [27]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Treatment / Management. Muscular rigidity\u00a0is thought\u00a0to be the primary cause of hyperthermia and death so patients with severe symptoms should\u00a0be rapidly cooled. If benzodiazepines do not sufficiently control muscle spasm or temperature is greater than 41.1 C,\u00a0intubation with neuromuscular blockade and paralysis can\u00a0be considered. [12] In cases\u00a0refractory to supportive care,\u00a0cyproheptadine or chlorpromazine, which have anti-serotonergic properties, can be administered; although, it is unclear if\u00a0these medications\u00a0alter patient outcome. [27] [28] Cyproheptadine does not have an IV formulation and must, therefore,\u00a0be administered\u00a0via a nasogastric or orogastric tube. [29] There is no role for acetaminophen, NSAIDs, or aspirin in control of hyperthermia as\u00a0the increased temperature\u00a0is not caused\u00a0by a change in the hypothalamic temperature set point. [27]"}
{"id": "article-30379_16", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Differential Diagnosis", "content": "Serotonin toxicity should not\u00a0be confused\u00a0with the neuroleptic malignant syndrome (NMS) which usually has an insidious onset of bradykinesia, \"lead pipe\"\u00a0rigidity and other extrapyramidal symptoms. [13] Duration of NMS is on the order of weeks, significantly longer than serotonin toxicity, which usually resolves within 24 hours of discontinuation of serotonergic therapies [29]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Differential Diagnosis. Serotonin toxicity should not\u00a0be confused\u00a0with the neuroleptic malignant syndrome (NMS) which usually has an insidious onset of bradykinesia, \"lead pipe\"\u00a0rigidity and other extrapyramidal symptoms. [13] Duration of NMS is on the order of weeks, significantly longer than serotonin toxicity, which usually resolves within 24 hours of discontinuation of serotonergic therapies [29]"}
{"id": "article-30379_17", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Prognosis", "content": "Prognosis is good, and full\u00a0recovery is expected. [29] The median length of stay for these SSRI overdose admissions was 15.3 hours in one study. [8] Mild cases can\u00a0be observed\u00a0in the emergency department for\u00a0at least\u00a06 hours before being discharged safely home. [12] Pharmacokinetics of the specific drug involved appear to affect duration; fluoxetine has a longer half-life than other SSRIs at\u00a04 to\u00a06 days. [7] [29] Patients with severe symptoms should be\u00a0dispositioned\u00a0to the intensive care unit.", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Prognosis. Prognosis is good, and full\u00a0recovery is expected. [29] The median length of stay for these SSRI overdose admissions was 15.3 hours in one study. [8] Mild cases can\u00a0be observed\u00a0in the emergency department for\u00a0at least\u00a06 hours before being discharged safely home. [12] Pharmacokinetics of the specific drug involved appear to affect duration; fluoxetine has a longer half-life than other SSRIs at\u00a04 to\u00a06 days. [7] [29] Patients with severe symptoms should be\u00a0dispositioned\u00a0to the intensive care unit."}
{"id": "article-30379_18", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Enhancing Healthcare Team Outcomes", "content": "SSRIs are prescribed by many healthcare workers including the primary care provider, psychiatrist, pain specialist, and the nurse practitioner. Unlike their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are much safer in overdose. [1] However, at the same time SSRIs are also associated with several serious adverse effects that need close monitoring. All clinicians who prescribe these drugs should educate the patient on the potential adverse effects. Nursing staff can also counsel the patients, monitor treatment effectiveness, watch for adverse drug reactions, and alert the prescriber regarding any issues that arise. In addition, the pharmacist has to make sure that the patient is not on any other medication that may lead to a drug-drug interaction with the SSRI.\u00a0 More important the pharmacist should ensure that multiple clinicians do not prescribe similar agents leading to polypharmacy and report concerns to the clinical team. An interprofessional approach between clinicians and pharmacists working together will result in the best outcomes. [Level 5]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Enhancing Healthcare Team Outcomes. SSRIs are prescribed by many healthcare workers including the primary care provider, psychiatrist, pain specialist, and the nurse practitioner. Unlike their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are much safer in overdose. [1] However, at the same time SSRIs are also associated with several serious adverse effects that need close monitoring. All clinicians who prescribe these drugs should educate the patient on the potential adverse effects. Nursing staff can also counsel the patients, monitor treatment effectiveness, watch for adverse drug reactions, and alert the prescriber regarding any issues that arise. In addition, the pharmacist has to make sure that the patient is not on any other medication that may lead to a drug-drug interaction with the SSRI.\u00a0 More important the pharmacist should ensure that multiple clinicians do not prescribe similar agents leading to polypharmacy and report concerns to the clinical team. An interprofessional approach between clinicians and pharmacists working together will result in the best outcomes. [Level 5]"}
{"id": "article-30379_19", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Enhancing Healthcare Team Outcomes", "content": "Clear, closed-loop communication between pre-hospital, regional poison control center, emergency department, and intensive care staff is essential to make sure that patients prescribed SSRI receive the appropriate\u00a0level of care while safely allocating resources. [30]", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Enhancing Healthcare Team Outcomes. Clear, closed-loop communication between pre-hospital, regional poison control center, emergency department, and intensive care staff is essential to make sure that patients prescribed SSRI receive the appropriate\u00a0level of care while safely allocating resources. [30]"}
{"id": "article-30379_20", "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}